Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study

Jul. 14, 2022 4:16 PM ETOncternal Therapeutics, Inc. (ONCT)ABBVBy: Anuron Mitra, SA News Editor

Lymphoma Cancer Cell


  • Oncternal Therapeutics (NASDAQ:ONCT) on Thursday said it had entered into a clinical trial collaboration with AbbVie (ABBV) company Pharmacyclics to support its phase 3 lymphoma study.
  • ONCT stock gained ~9% to $1.22 after hours.
  • As per the terms of the collaboration, Pharmacyclics will supply its lymphoma medicine ibrutinib for ONCT's late-stage trial.
  • ONCT's late-stage trial, called ZILO-301, is evaluating the company's monoclonal antibody zilovertamab in combination with ibrutinib for the treatment of relapsed or refractory mantle cell lymphoma, a rare type of cancer of the lymphatic system.
  • The agreement also includes the supply of ibrutinib for ZILO-302, an open-label companion study of zilovertamab plus ibrutinib for patients who have progressive disease during the initial four months of ibrutinib monotherapy from the ZILO-301 study.
  • Pharmacyclics' ibrutinib is FDA approved under the brand name Imbruvica for the treatment of various types of lymphoma and leukemia.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.